These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38014605)

  • 41. Identification of synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
    Lin S; Sui J; Cotard S; Fung B; Andersen J; Zhu P; El Messadi N; Lehar J; Lee M; Staunton J
    Assay Drug Dev Technol; 2010 Dec; 8(6):669-84. PubMed ID: 21050065
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An update on new and emerging therapies for cystic fibrosis.
    Hudock KM; Clancy JP
    Expert Opin Emerg Drugs; 2017 Dec; 22(4):331-346. PubMed ID: 29264936
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
    Bell SC; De Boeck K; Amaral MD
    Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simplifying CFTR modulation therapy in cystic fibrosis.
    Arch Dis Child; 2023 Aug; 108(8):615. PubMed ID: 37468145
    [No Abstract]   [Full Text] [Related]  

  • 45. Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms.
    Cao L; Wu Y; Gong Y; Zhou Q
    Eur J Med Chem; 2024 Feb; 265():116120. PubMed ID: 38194776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR.
    Bose SJ; Krainer G; Ng DRS; Schenkel M; Shishido H; Yoon JS; Haggie PM; Schlierf M; Sheppard DN; Skach WR
    J Cyst Fibros; 2020 Mar; 19 Suppl 1(Suppl 1):S25-S32. PubMed ID: 31902693
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis.
    McCarthy C; Brewington JJ; Harkness B; Clancy JP; Trapnell BC
    Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29563174
    [No Abstract]   [Full Text] [Related]  

  • 49. Optimising the care and quality of life of people with cystic fibrosis: the influence of cystic fibrosis transmembrane conductance regulator modulators.
    Shaw N; Collins S; Smith T; McCulloch A; Ketchell I; Edwards V; Blaikie L; Daniels T
    Br J Hosp Med (Lond); 2021 Nov; 82(11):1-6. PubMed ID: 34817261
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Therapeutic update in cystic fibrosis].
    Durupt S; Nove Josserand R; Durieu I
    Rev Med Interne; 2014 Jun; 35(6):388-92. PubMed ID: 24309546
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CFTR dysfunction and targeted therapies: A vision from non-cystic fibrosis bronchiectasis and COPD.
    Martinez-Garcia MA; Sierra-Párraga JM; Quintana E; López-Campos JL
    J Cyst Fibros; 2022 Sep; 21(5):741-744. PubMed ID: 35551858
    [No Abstract]   [Full Text] [Related]  

  • 52. Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators.
    Fiedorczuk K; Chen J
    Science; 2022 Oct; 378(6617):284-290. PubMed ID: 36264792
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.
    Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA
    Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242
    [No Abstract]   [Full Text] [Related]  

  • 54. CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation.
    Phuan PW; Haggie PM; Tan JA; Rivera AA; Finkbeiner WE; Nielson DW; Thomas MM; Janahi IA; Verkman AS
    J Cyst Fibros; 2021 May; 20(3):452-459. PubMed ID: 32674984
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Proteomic Survey of the Cystic Fibrosis Transmembrane Conductance Regulator Surfaceome.
    Iazzi M; Sadeghi S; Gupta GD
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511222
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
    Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
    BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date.
    Becq F
    Drugs; 2010 Feb; 70(3):241-59. PubMed ID: 20166764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of protein repair therapy in the treatment of cystic fibrosis.
    Rubenstein RC; Zeitlin PL
    Curr Opin Pediatr; 1998 Jun; 10(3):250-5. PubMed ID: 9716885
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular Genetics of Cystic Fibrosis Transmembrane Conductance Regulator: Genotype and Phenotype.
    Sosnay PR; Raraigh KS; Gibson RL
    Pediatr Clin North Am; 2016 Aug; 63(4):585-98. PubMed ID: 27469177
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis.
    Taylor-Cousar JL; Shteinberg M; Cohen-Cymberknoh M; Jain R
    Clin Ther; 2023 Mar; 45(3):278-289. PubMed ID: 36841738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.